References
- Aurora SK , DodickDW , TurkelCCet al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial . Cephalalgia30 ( 7 ), 793 – 803 ( 2010 ).
- Diener HC , DodickDW , AuroraSKet al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial . Cephalalgia30 ( 7 ), 804 – 814 ( 2010 ).
- Silberstein SD , BlumenfeldAM , CadyRKet al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline . J. Neurol. Sci.331 ( 1–2 ), 48 – 56 ( 2013 ).
- Jackson JL , KuriyamaA , HayashinoY . Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis . JAMA307 ( 16 ), 1736 – 1745 ( 2012 ).
- Peña E . Treatment with botulinum toxin: an update . World J. Neurol.3 ( 3 ), 29 – 41 ( 2013 ).
- Jakubowski M , McallisterPJ , BajwaZH , WardTN , SmithP , BursteinR . Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A . Pain125 , 286 – 295 ( 2006 ).
- Lionetto L , NegroA , PalmisaniSet al. Emerging treatment for chronic migraine and refractory chronic migraine . Expert Opin. Emerg. Drugs17 ( 3 ), 393 – 406 ( 2012 ).
- Tighe AP , SchiavoG . Botulinum neurotoxins: mechanism of action . Toxicon67 , 87 – 93 ( 2013 ).
- Simpson L . The life history of a botulinum toxin molecule . Toxicon68 , 40 – 59 ( 2013 ).
- Durham PL , CadyR . Insights into the mechanism of onabotulinumtoxinA in chronic migraine . Headache51 ( 10 ), 1573 – 1577 ( 2011 ).
- Matak I , LackovicZ . Botulinum toxin A, brain and pain . Prog. Neurobiol. ( 2014 ) ( In Press ).
- Arezzo JC . Possible mechanisms for the effects of botulinum toxin on pain . Clin. J. Pain18 ( 6 Suppl. ), S125 – S132 ( 2002 ).
- Burstein R , ZhangX , LevyD , AokiKR , BrinMF . Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains . Cephalalgia ( 2014 ) ( In Press ).
- Gazerani P , AuS , DongX , KumarU , Arendt-NielsenL , CairnsBE . Botulinum neurotoxin type A (BoNTA) decreases the mechanical sensitivity of nociceptors and inhibits neurogenic vasodilation in a craniofacial muscle targeted for migraine prophylaxis . Pain151 ( 3 ), 606 – 616 ( 2010 ).
- Cairns BE , DongX , MannMKet al. Systemic administration of monosodium glutamate elevates intramuscular glutamate levels and sensitizes rat masseter muscle afferent fibers . Pain132 ( 1–2 ), 33 – 41 ( 2007 ).
- Schueler M , MesslingerK , DuxM , NeuhuberWL , De ColR . Extracranial projections of meningeal afferents and their impact on meningeal nociception and headache . Pain154 ( 9 ), 1622 – 1631 ( 2013 ).
- Bittencourt Da Silva L , KulasD , KarshenasAet al. Time course analysis of the effects of botulinum neurotoxin type A on pain and vasomotor responses evoked by glutamate injection into human temporalis muscles . Toxins (Basel)6 ( 2 ), 592 – 607 ( 2014 ).
- Bittencourt Da Silva L , KarshenasA , BachFW , RasmussenS , Arendt-NielsenL , GazeraniP . Blockade of glutamate release by botulinum neurotoxin type A in humans: a dermal microdialysis study . Pain Res. Manag.19 ( 3 ), 126 – 132 ( 2014 ).
- Blumenfeld A , AshkenaziA , NapchanUet al. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches – a narrative review . Headache53 ( 3 ), 437 – 446 ( 2013 ).
- Mustafa G , AndersonEM , Bokrand-DonatelliY , NeubertJK , CaudleRM . Anti-nociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type A . Pain154 ( 11 ), 2547 – 2553 ( 2013 ).